Companies Dominating the Testosterone Injectable Landscape
- Bayer AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Endo Pharmaceuticals Inc.
- Eli Lilly & Company
- Kyowa Kirin International plc
- Mylan N.V.
- Novartis AG
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of testosterone injectable is assessed at USD 2.3 billion.
The testosterone injectable market size was over USD 2.16 billion in 2024 and is projected to reach USD 3.55 billion by 2037, growing at around 3.9% CAGR during the forecast period i.e., between 2025-2037. The market growth is due to rapidly growing geriatric population across the world, and the high prevalence of testosterone deficiency among people worldwide.
Europe industry is estimated to account for largest revenue share by 2037, propelled by presence of various medical centers, and rising government initiatives in the region.
The major players in the market are Bayer AG, Endo Pharmaceuticals Inc., Eli Lilly & Company, Kyowa Kirin International plc, Mylan N.V., Novartis AG
